Influence of Cytochrome P450 2D6 Polymorphisms on the Efficacy of Oral Propranolol in Treating Infantile Hemangioma

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2020 Mar 29

PMID 32219146

Citations 4

Authors

Lidan Wang

Kai Zheng

Xinlin Li

Yang Wang

Qiong Xu

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this study is to evaluate the association of genetic polymorphisms in Cytochrome P450 2D6(CYP2D6) and the change in VEGF levels with the response to propranolol in patients with Infantile hemangiomas (IH).

Methods: IH patients who underwent over six months of propranolol therapy and received oral propranolol only were enrolled. The target dose of propranolol was 1 mg kgday. Deoxyribonucleic acid was obtained from venous blood leukocytes. Genotypes of CYP2D6 (rs1065852 and rs1135840) were tested by polymerase chain reaction (PCR) and by sequencing the products. Baseline serum VEGF and serum VEGF one month after treatment were measured. The clinical responses after six months of treatment were evaluated. Genotypes of CYP2D6 (rs1065852 and rs1135840) and VEGF levels were compared between good responders and poor-to-moderate responders.

Results: 72 patients were enrolled in the study. Patients with CYP2D6 (rs1135840) G/G homozygote had the highest response rate to propranolol. No significant association was found between the response rates and CYP2D6 (rs1065852) polymorphism. No significant differences were found in baseline serum VEGF, serum VEGF one month after treatment, and VEGF ratio between good responders and poor-to-moderate responders.

Conclusion: The response to propranolol treatment in IH patients was associated with the gene polymorphism of CYP2D6 (rs1135840). A low-dose propranolol regimen was effective and safe in young infants with IH. The change of serum VEGF levels after one month's treatment could not be used to predict the response rate to propranolol.

Citing Articles

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy.

Duarte J, Thomas C, Lee C, Huddart R, Agundez J, Baye J Clin Pharmacol Ther. 2024; 116(4):939-947.

PMID: 38951961 PMC: 11502236. DOI: 10.1002/cpt.3351.

Plasma Drug Concentration of Propranolol and Genetic Study in Chinese Han Patients With Infantile Haemangioma.

Li L, Yu L, He H, Wei L, Xu Z, Zhao L Front Pediatr. 2022; 10:849496.

PMID: 35586822 PMC: 9108385. DOI: 10.3389/fped.2022.849496.

Paediatrics: how to manage infantile haemangioma.

Kim J, Lam J Drugs Context. 2021; 10.

PMID: 33889196 PMC: 8029639. DOI: 10.7573/dic.2020-12-6.

Morphological, genetic and clinical correlations in infantile hemangiomas and their mimics.

Luca A, Miron I, Trandafir L, Cojocaru E, Paduret I, Trandafirescu M Rom J Morphol Embryol. 2021; 61(3):687-695.

PMID: 33817710 PMC: 8112746. DOI: 10.47162/RJME.61.3.07.

References

Phillips R, Lokmic Z, Crock C, Penington A . Infantile haemangiomas that failed treatment with propranolol: clinical and histopathological features. J Paediatr Child Health. 2014; 50(8):619-25. DOI: 10.1111/jpc.12600. View

Ji Y, Chen S, Xu C, Li L, Xiang B . The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action. Br J Dermatol. 2014; 172(1):24-32. DOI: 10.1111/bjd.13388. View

Wedgeworth E, Glover M, Irvine A, Neri I, Baselga E, Clayton T . Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey. Br J Dermatol. 2015; 174(3):594-601. DOI: 10.1111/bjd.14233. View

Leaute-Labreze C, Prey S, Ezzedine K . Infantile haemangioma: part I. Pathophysiology, epidemiology, clinical features, life cycle and associated structural abnormalities. J Eur Acad Dermatol Venereol. 2011; 25(11):1245-53. DOI: 10.1111/j.1468-3083.2011.04102.x. View

Leaute-Labreze C, Harper J, Hoeger P . Infantile haemangioma. Lancet. 2017; 390(10089):85-94. DOI: 10.1016/S0140-6736(16)00645-0. View

Haggstrom A, Drolet B, Baselga E, Chamlin S, Garzon M, Horii K . Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics. 2006; 118(3):882-7. DOI: 10.1542/peds.2006-0413. View

Johansson I, Oscarson M, Yue Q, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M . Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol. 1994; 46(3):452-9. View

Kar Y, Ozdemir Z, Acu B, Bor O . Infantile hemangioma: Efficacy of low-dose propranolol and of intralesional bleomycin injection for propranolol non-response. Pediatr Int. 2019; 61(5):459-464. DOI: 10.1111/ped.13830. View

Chen X, Ma G, Huang J, Chen H, Jin Y, Ye X . Serum-level changes of vascular endothelial growth factor in children with infantile hemangioma after oral propranolol therapy. Pediatr Dermatol. 2013; 30(5):549-53. DOI: 10.1111/pde.12192. View

10.

Storch C, Hoeger P . Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol. 2010; 163(2):269-74. DOI: 10.1111/j.1365-2133.2010.09848.x. View

11.

Zhu L, Xie J, Liu Z, Huang Z, Huang M, Yin H . Pigment epithelium-derived factor/vascular endothelial growth factor ratio plays a crucial role in the spontaneous regression of infant hemangioma and in the therapeutic effect of propranolol. Cancer Sci. 2018; 109(6):1981-1994. PMC: 5989849. DOI: 10.1111/cas.13611. View

12.

Novoa M, Baselga E, Beltran S, Giraldo L, Shahbaz A, Pardo-Hernandez H . Interventions for infantile haemangiomas of the skin. Cochrane Database Syst Rev. 2018; 4:CD006545. PMC: 6513200. DOI: 10.1002/14651858.CD006545.pub3. View

13.

Lee J, Vinayagamoorthy N, Han K, Kwok S, Ju J, Park K . Association of Polymorphisms of Cytochrome P450 2D6 With Blood Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2015; 68(1):184-90. DOI: 10.1002/art.39402. View

14.

Tollefson M, Frieden I . Early growth of infantile hemangiomas: what parents' photographs tell us. Pediatrics. 2012; 130(2):e314-20. DOI: 10.1542/peds.2011-3683. View

15.

Lou Y, Peng W, Cao Y, Cao D, Xie J, Li H . The effectiveness of propranolol in treating infantile haemangiomas: a meta-analysis including 35 studies. Br J Clin Pharmacol. 2013; 78(1):44-57. PMC: 4168379. DOI: 10.1111/bcp.12235. View

16.

Lopez-Gutierrez J . Clinical and economic impact of surgery for treating infantile hemangiomas in the era of propranolol: overview of single-center experience from La Paz Hospital, Madrid. Eur J Pediatr. 2018; 178(1):1-6. DOI: 10.1007/s00431-018-3290-z. View

17.

Chong J, Prey S, Mya H, Delarue A, Labreze C . Can the extent of heart rate reduction predict the clinical response of infantile haemangiomas to propranolol?. Br J Dermatol. 2017; 178(3):e196-e197. DOI: 10.1111/bjd.15966. View

18.

Lai M, Wang S, Lai M, Lin E, Tse M, Huang J . Propranolol disposition in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther. 1995; 58(3):264-8. DOI: 10.1016/0009-9236(95)90242-2. View

19.

Pandey V, Tiwari P, Sharma S, Kumar R, Singh O . Role of intralesional bleomycin and intralesional triamcinolone therapy in residual haemangioma following propranolol. Int J Oral Maxillofac Surg. 2018; 47(7):908-912. DOI: 10.1016/j.ijom.2018.03.024. View

20.

Tan C, Itinteang T, Leadbitter P, Marsh R, Tan S . Low-dose propranolol regimen for infantile haemangioma. J Paediatr Child Health. 2014; 51(4):419-24. DOI: 10.1111/jpc.12720. View